Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) – Investment analysts at Roth Capital issued their Q1 2025 earnings per share estimates for shares of Cellectar Biosciences in a research note issued on Monday, November 18th. Roth Capital analyst J. Aschoff expects that the biopharmaceutical company will earn ($0.26) per share for the quarter. The consensus […]